Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2008 Sep;51(9):1570-3.
doi: 10.1007/s00125-008-1078-9. Epub 2008 Jul 8.

Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?

D N Sang  1 , P A D'Amore
Affiliations
Comment

Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy?

D N Sang et al. Diabetologia. 2008 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Duality of interest DNS has served on advisory boards for Novartis, QLT and OSI-Eyetech, and received research funds from QLT.

Comment on

References

    1. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F 3rd (1989) Detection of diabetic macular edema. Ophthalmoscopy versus photography—Early Treatment Diabetic Retinopathy Study report number 5. The ETDRS Research Group. Ophthalmology 96:746–750 - PubMed
    1. Early Treatment Diabetic Retinopathy Study Research Group (1991) Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 98:741–756 - PubMed
    1. Simó R, Hernández C (2008) Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia doi 10.1007/s00125-008-0989-9 - DOI - PubMed
    1. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431 - PubMed
    1. Brown DM, Regillo CD (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144:627–637 - PubMed

MeSH terms

Substances